Bad facts. It was not an easy sell at all 2014-2017 when it was double and triple step edits. It only became easier when we drove enough volume to get coverage. I am no longer with Celgene or BMY, but do market research now. I can assure you that industry wide, the people that counted thought Otezla had great sales people. Sure, I guess there were a few pretty ones, but the scoreboard says they took a drug that barely works and drove it to 2 plus billion in sales and then sold it to Amgen for 13 billion. It wasn't the science or the efficacy or the outstanding molecule that did that. It was the Celgene sales force. As for Forest, they were terrible and nothing like Celgene. Forest was cheap, and mean, and aggressive. Kinda like a few of my boyfriends.